Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04565327 · ClinicalTrials.gov registry record · Phase 2
Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma
A Phase 2 study, sponsored by Zhen Wang, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04565327 is a Phase 2 study that was terminated before completion, run by Zhen Wang, MD. The registered enrollment target is 7 participants.
The verdict
NCT04565327, a Phase 2 study, was terminated before completion, sponsored by Zhen Wang, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This phase II trial investigates whether magnetic resonance imaging (MRI) using hyperpolarized carbon-13 (13C) pyruvate can be useful for evaluating early treatment response in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or spread to other places in the body (metastatic). Hyperpolarized 13C pyruvate is different from standard clinical MRI contrast (e.g. gadolinium) in that it provides information on how a tumor processes nutrients. MRI is used to see tumor uptake and breakdown of hyperpolarized carbon-13 pyruvate molecules, which can tell how the tumor processes nutrients. Hyperpolarized 13C pyruvate MRI may help in understanding how the tumor responds to the treatments patients may be receiving.
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- DRUG Hyperpolarized Carbon C 13 Pyruvate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04565327
The ClinicalTrials.gov registry entry for NCT04565327 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zhen Wang, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT04565327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04565327 about?
NCT04565327 is a clinical study titled "Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma". This phase II trial investigates whether magnetic resonance imaging (MRI) using hyperpolarized carbon-13 (13C) pyruvate can be useful for evaluating early treatment response in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or spread to other place...
What is the current status of trial NCT04565327?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2020-08-14. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT04565327?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Hyperpolarized Carbon C 13 Pyruvate (DRUG).
Who is sponsoring clinical trial NCT04565327?
This trial is sponsored by Zhen Wang, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.